Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
New single-arm, open-label data extend the body of evidence supporting consistent clinical benefit and safety with Camzyos, adding to the longest-running clinical development experience for a cardiac myosin inhibitor (CMI) in symptomatic oHCM
Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings
Bristol Myers Squibb (NYSE: BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. EXPLORER-LTE is the largest and longest evaluation of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients treated with Camzyos, the most-studied cardiac myosin inhibitor (CMI) and a standard of care for patients with oHCM in New York Heart Association (NYHA) class II-III. These data add to the understanding that the effects of Camzyos are sustained for up to five years with continuous, consistent treatment. Additional presentations at ESC Congress from COLLIGO-HCM, a global retrospective real-world data study, add to the well-established real-world evidence supporting Camzyos, helping inform treatment decisions for people living with the condition.
